Evidence for field cancerization of the prostate

Prostate

Volumn 69, Issue 13, 2009, Pages 1470-1479

  Nonn, Larisa ^a   Ananthanarayanan, Vijayalakshmi ^a   Gann, Peter H ^a,b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Biomarkers; Field effects; Prostate cancer

Indexed keywords

BIOLOGICAL MARKER; DNA;

ANGIOGENESIS; CANCER GRADING; CANCER PREVENTION; CARCINOGENESIS; CARCINOGENIC ACTIVITY; CASE CONTROL STUDY; CELL STRUCTURE; CLINICAL EVALUATION; DISEASE MARKER; DNA DAMAGE; DNA METHYLATION; DNA REPAIR; GENE EXPRESSION; GENE EXPRESSION REGULATION; HETEROZYGOSITY LOSS; HUMAN; INFRARED SPECTROSCOPY; PREDICTION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATIC INTRAEPITHELIAL NEOPLASIA; PROTEIN EXPRESSION; REVIEW;

EPIGENESIS, GENETIC; GENETIC MARKERS; HUMANS; MALE; PROSTATE; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 69449107322     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20983     Document Type: Review

References (59)

1. Slaughter DP, Southwick HW, Smejkal W. Field cancerization in oral stratified squamous epithelium; clinical implications of multicentric origin. Cancer 1953;6(5):963-968.
2. Jothy S, Slesak B, Harlozinska A, Lapinska J, Adamiak J, Rabczynski J. Field effect of human colon carcinoma on normal mucosa: Relevance of carcinoembryonic antigen expression. Tumour Biol 1996;17(1):58-64. (Pubitemid 126507121)
3. Takahashi T, Habuchi T, Kakehi Y, Mitsumori K, Akao T, Terachi T, Yoshida O. Clonal and chronological genetic analysis of multifocal cancers of the bladder and upper urinary tract. Cancer Res 1998;58(24):5835-5841. (Pubitemid 29006426)
4. Franklin WA, Gazdar AF, Haney J, Wistuba II, La Rosa FG, Kennedy T, Ritchey DM, Miller YE. Widely dispersed p53 mutation in respiratory epithelium. A novel mechanism for field carcinogenesis. J Clin Invest 1997;100(8):2133-2137. (Pubitemid 27459370)
5. Rosenthal AN, Ryan A, Hopster D, Jacobs IJ. Molecular evidence of a common clonal origin and subsequent divergent clonal evolution in vulval intraepithelial neoplasia, vulval squamous cell carcinoma and lymph node metastases. Int J Cancer 2002;99(4):549-554. (Pubitemid 34461607)
6. Prevo LJ, Sanchez CA, Galipeau PC, Reid BJ. p53-mutant clones and field effects in Barrett's esophagus. Cancer Res 1999;59(19):4784-4787.
7. Chu TY, Shen CY, Lee HS, Liu HS. Monoclonality and surface lesion-specific microsatellite alterations in premalignant and malignant neoplasia of uterine cervix: A local field effect of genomic instability and clonal evolution. Genes Chromosomes Cancer 1999;24(2):127-134.
8. Forsti A, Louhelainen J, Soderberg M, Wijkstrom H, Hemminki K. Loss of heterozygosity in tumour-adjacent normal tissue of breast and bladder cancer. Eur J Cancer 2001;37(11):1372-1380. (Pubitemid 32588748)
9. Stern RS, Bolshakov S, Nataraj AJ, Ananthaswamy HN. p53 mutation in nonmelanoma skin cancers occurring in psoralen ultraviolet a-treated patients: Evidence for heterogeneity and field cancerization. J Invest Dermatol 2002;119(2):522-526. (Pubitemid 35001966)
10. Qian J, Wollan P, Bostwick DG. The extent and multicentricity of high-grade prostatic intraepithelial neoplasia in clinically localized prostatic adenocarcinoma. Hum Pathol 1997;28(2):143-148. (Pubitemid 27069177)
11. De Marzo AM, Platz EA, Sutcliffe S, Xu J, Gronberg H, Drake CG, Nakai Y, Isaacs WB, Nelson WG. Inflammation in prostate carcinogenesis. Nat Rev Cancer 2007;7(4):256-269.
12. Vukovic B, Park PC, Al-Maghrabi J, Beheshti B, Sweet J, Evans A, Trachtenberg J, Squire J. Evidence of multifocality of telomere erosion in high-grade prostatic intraepithelial neoplasia (HPIN) and concurrent carcinoma. Oncogene 2003;22(13):1978-1987.
13. De Marzo AM, Marchi VL, Epstein JI, Nelson WG. Proliferative inflammatory atrophy of the prostate: Implications for prostatic carcinogenesis. Am J Pathol 1999;155(6):1985-1992.
14. Franks LM. Atrophy and hyperplasia in the prostate proper. J Pathol Bacteriol 1954;68(2):617-621.
15. Zha S, Gage WR, Sauvageot J, Saria EA, Putzi MJ, Ewing CM, Faith DA, Nelson WG, De Marzo AM, Isaacs WB. Cyclooxygenase-2 is up-regulated in proliferative inflammatory atrophy of the prostate, but not in prostate carcinoma. Cancer Res 2001;61(24):8617-8623. (Pubitemid 34013865)
16. Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L. Independent origin of multiple foci of prostatic intraepithelial neoplasia: Comparison with matched foci of prostate carcinoma. Cancer 1998;83(9):1995-2002. (Pubitemid 28503732)
17. Meeker AK, Hicks JL, Platz EA, March GE, Bennett CJ, Delannoy MJ, DeMarzo AM. Telomere shortening is an early somatic DNA alteration in human prostate tumorigenesis. Cancer Res 2002;62(22):6405-6409.
18. Koeneman KS, Pan CX, Jin JK, Pyle JM III, Flanigan RC, Shankey TV, Diaz MO. Telomerase activity, telomere length, and DNA ploidy in prostatic intraepithelial neoplasia (PIN). J Urol 1998;160(4):1533-1539.
19. Mairinger T, Mikuz G, Gschwendtner A. Nuclear chromatin texture analysis of nonmalignant tissue can detect adjacent prostatic adenocarcinoma. Prostate 1999;41(1):12-19. (Pubitemid 29390411)
20. Veltri RW, Khan MA, Miller MC, Epstein JI, Mangold LA, Walsh PC, Partin AW. Ability to predict metastasis based on pathology findings and alterations in nuclear structure of normal-appearing and cancer peripheral zone epithelium in the prostate. Clin Cancer Res 2004;10(10):3465-3473.
21. Montironi R, Diamanti L, Pomante R, Thompson D, Bartels PH. Subtle changes in benign tissue adjacent to prostate neoplasia detected with a Bayesian belief network. J Pathol 1997;182(4):442-449. (Pubitemid 27317210)
22. Chandran UR, Dhir R, Ma C, Michalopoulos G, Becich M, Gilbertson J. Differences in gene expression in prostate cancer, normal appearing prostate tissue adjacent to cancer and prostate tissue from cancer free organ donors. BMC Cancer 2005;5(1):45. (Pubitemid 41461084)
23. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S, Michalopoulos G, Becich M, Luo JH. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004;22(14):2790-2799. (Pubitemid 41079896)
24. Rizzi F, Belloni L, Crafa P, Lazzaretti M, Remondini D, Ferretti S, Cortellini P, Corti A, Bettuzzi S. A novel gene signature for molecular diagnosis of human prostate cancer by RT-qPCR. PLoS ONE 2008;3(10):e3617.
25. Kaklamani V. A genetic signature can predict prognosis and response to therapy in breast cancer: Oncotype DX. Expert Rev Mol Diagn 2006;6(6):803-809. (Pubitemid 44911030)
26. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alteration of proliferation and apoptotic markers in normal and premalignant tissue associated with prostate cancer. BMC Cancer 2006;6:73. (Pubitemid 46277068)
27. Santinelli A, Mazzucchelli R, Barbisan F, Lopez-Beltran A, Cheng L, Scarpelli M, Montironi R. alpha-Methylacyl coenzyme Aracemase, Ki-67, and topoisomerase IIalpha in cystoprostatectomies with incidental prostate cancer. Am J Clin Pathol 2007;128(4):657-666. (Pubitemid 47584446)
28. Ananthanarayanan V, Deaton RJ, Yang XJ, Pins MR, Gann PH. Alpha-methylacyl-CoA racemase (AMACR) expression in normal prostatic glands and high-grade prostatic intraepithelial neoplasia (HGPIN): Association with diagnosis of prostate cancer. Prostate 2005;63(4):341-346. (Pubitemid 40664346)
29. Bonkhoff H, Stein U, Welter C, Remberger K. Differential expression of the pS2 protein in the human prostate and prostate cancer: Association with premalignant changes and neuroendocrine differentiation. Hum Pathol 1995;26(8):824-828.
30. Ayala G, Thompson T, Yang G, Frolov A, Li R, Scardino P, Ohori M, Wheeler T, Harper W. High levels of phosphorylated form of Akt-1 in prostate cancer and non-neoplastic prostate tissues are strong predictors of biochemical recurrence. Clin Cancer Res 2004;10(19):6572-6578. (Pubitemid 39346553)
31. Slater M, Danieletto S, Barden JA. Expression of the apoptotic calcium channel P2X7 in the glandular epithelium. J Mol Histol 2005;36(3):159-165.
32. Olapade-Olaopa EO, MacKay EH, Taub NA, Sandhu DP, Terry TR, Habib FK. Malignant transformation of human prostatic epithelium is associated with the loss of androgen receptor immunoreactivity in the surrounding stroma. Clin Cancer Res 1999;5(3):569-576.
33. Dhir R, Vietmeier B, Arlotti J, Acquafondata M, Landsittel D, Masterson R, Getzenberg RH. Early identification of individuals with prostate cancer in negative biopsies. J Urol 2004;171(4):1419-1423. (Pubitemid 38365385)
34. Uetsuki H, Tsunemori H, Taoka R, Haba R, Ishikawa M, Kakehi Y. Expression of a novel biomarker, EPCA, in adenocarcinomas and precancerous lesions in the prostate. J Urol 2005;174(2):514-518. (Pubitemid 40981588)
35. Hansel DE, DeMarzo AM, Platz EA, Jadallah S, Hicks J, Epstein JI, Partin AW, Netto GJ. Early prostate cancer antigen expression in predicting presence of prostate cancer in men with histologically negative biopsies. J Urol 2007;177(5):1736-1740. (Pubitemid 46560651)
36. Paul B, Dhir R, Landsittel D, Hitchens MR, Getzenberg RH. Detection of prostate cancer with a blood-based assay for early prostate cancer antigen. Cancer Res 2005;65(10):4097-4100. (Pubitemid 40775646)
37. Cohen BL, Gomez P, Omori Y, Duncan RC, Civantos F, Soloway MS, Lokeshwar VB, Lokeshwar BL. Cyclooxygenase-2 (COX-2) expression is an independent predictor of prostate cancer recurrence. Int J Cancer 2006;119(5):1082-1087. (Pubitemid 44116917)
38. Marks LS, Bostwick DG. Prostate cancer specificity of PCA3 gene testing: Examples from clinical practice. Rev Urol 2008;10(3):175-181.
39. Popa I, Fradet Y, Beaudry G, Hovington H, Tetu B. Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 2007;20(11):1121-1127. (Pubitemid 47609070)
40. Nakayama M, Gonzalgo ML, Yegnasubramanian S, Lin X, De Marzo AM, Nelson WG. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004;91(3):540-552.
41. Hanson JA, Gillespie JW, Grover A, Tangrea MA, Chuaqui RF, Emmert-Buck MR, Tangrea JA, Libutti SK, Linehan WM, Woodson KG. Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst 2006;98(4):255-261. (Pubitemid 43264709)
42. Henrique R, Jeronimo C, Teixeira MR, Hoque MO, Carvalho AL, Pais I, Ribeiro FR, Oliveira J, Lopes C, Sidransky D. Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: Clues for clonal progression in prostate carcinogenesis. Mol Cancer Res 2006;4(1):1-8. (Pubitemid 43259884)
43. Mehrotra J, Varde S, Wang H, Chiu H, Vargo J, Gray K, Nagle RB, Neri JR, Mazumder A. Quantitative, spatial resolution of the epigenetic field effect in prostate cancer. Prostate 2008;68(2):152-160. (Pubitemid 351186227)
44. Aitchison A, Warren A, Neal D, Rabbitts P. RASSF1A promoter methylation is frequently detected in both pre-malignant and non-malignant microdissected prostatic epithelial tissues. Prostate 2007;67(6):638-644. (Pubitemid 46685284)
45. Krop I, Player A, Tablante A, Taylor-Parker M, Lahti-Domenici J, Fukuoka J, Batra SK, Papadopoulos N, Richards WG, Sugarbaker DJ, Wright RL, Shim J, Stamey TA, Sellers WR, Loda M, Meyerson M, Hruban R, Jen J, Polyak K. Frequent HIN-1 promoter methylation and lack of expression in multiple human tumor types. Mol Cancer Res 2004;2(9):489-494. (Pubitemid 39281730)
46. Malins DC, Johnson PM, Barker EA, Polissar NL, Wheeler TM, Anderson KM. Cancer-related changes in prostate DNA as men age and early identification of metastasis in primary prostate tumors. Proc Natl Acad Sci USA 2003;100(9):5401-5406.
47. Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Anderson KM. A cancer DNA phenotype in healthy prostates, conserved in tumors and adjacent normal cells, implies a relationship to carcinogenesis. Proc Natl Acad Sci USA 2005;102(52):19093-19096.
48. Malins DC, Gilman NK, Green VM, Wheeler TM, Barker EA, Vinson MA, Sayeeduddin M, Hellstrom KE, Anderson KM. Metastatic cancer DNA phenotype identified in normal tissues surrounding metastasizing prostate carcinomas. Proc Natl Acad Sci USA 2004;101(31):11428-11431. (Pubitemid 39038363)
49. Parr RL, Dakubo GD, Crandall KA, Maki J, Reguly B, Aguirre A, Wittock R, Robinson K, Alexander JS, Birch-Machin MA, Abdel-Malak M, Froberg MK, Diamandis EP, Thayer RE. Somatic mitochondrial DNA mutations in prostate cancer and normal appearing adjacent glands in comparison to age-matched prostate samples without malignant histology. J Mol Diagn 2006;8(3):312-319. (Pubitemid 44063807)
50. Siegal JA, Yu E, Brawer MK. Topography of neovascularity in human prostate carcinoma. Cancer 1995;75(10):2545-2551.
51. Montironi R, Diamanti L, Thompson D, Bartels HG, Bartels PH. Analysis of the capillary architecture in the precursors of prostate cancer: Recent findings and new concepts. Eur Urol 1996;30(2):191-200. (Pubitemid 26285534)
52. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005;310(5748):644-648. (Pubitemid 41528150)
53. Furusato B, Gao CL, Ravindranath L, Chen Y, Cullen J, McLeod DG, Dobi A, Srivastava S, Petrovics G, Sesterhenn IA. Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol 2008;21(2):67-75. (Pubitemid 351172158)
54. Mosquera JM, Perner S, Genega EM, Sanda M, Hofer MD, Mertz KD, Paris PL, Simko J, Bismar TA, Ayala G, Shah RB, Loda M, Rubin MA. Characterization of TMPRSS2-ERG fusion high-grade prostatic intraepithelial neoplasia and potential clinical implications. Clin Cancer Res 2008;14(11):3380-3385.
55. Rogerson L, Darby S, Jabbar T, Mathers ME, Leung HY, Robson CN, Sahadevan K, O'Toole K, Gnanapragasam VJ. Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int 2008;102(3):364-370. (Pubitemid 352019196)
56. Shukla CJ, Pennington CJ, Riddick AC, Sethia KK, Ball RY, Edwards DR. Laser-capture microdissection in prostate cancer research: Establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJU Int 2008;101(6):765-774.
57. Gann PH, Fought A, Deaton RJ, Catalona WJ, Vonesh E. Risk factors for prostate cancer detection after a negative biopsy: A novel multivariable longitudinal approach. J Clin Oncol, in review.
58. Fabian CJ, Kimler BF, Zalles CM, Khan QJ, Mayo MS, Phillips TA, Simonsen M, Metheny T, Petroff BK. Reduction in proliferation with six months of letrozole in women on hormone replacement therapy. Breast Cancer Res Treat 2007;106(1):75-84. (Pubitemid 47498093)
59. Valdman A, Jonmarker S, Ekman P, Egevad L. Cytological features of prostatic intraepithelial neoplasia. Diagn Cytopathol 2006;34(5):317-322.